Business & Industry News
Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria
Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim®, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa. AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration
AstraZeneca and Bristol-Myers Squibb have announced expansion of their worldwide collaboration to include the development and commercialisation of dapagliflozin in Japan. Dapagliflozin, one of two investigational drugs under joint development by the companies, is currently being studied in Phase III clinical trials in several countries, including the U.S., to assess its efficacy and safety as a once-daily treatment for type 2 diabetes. GSK analysis shows Seretide/Advair is a well tolerated and effective medicine
The U.S. Food and Drug Administration has posted a comprehensive review conducted by GlaxoSmithKline of its clinical and observational data that demonstrated better overall asthma control with the combination medicine Seretide/Advair (fluticasone propionate and salmeterol) than with a single medicine alone. Bayer Schering Pharma expands men's healthcare portfolio
Bayer Schering Pharma will develop and commercialise ProStrakan's Tostrex® in Canada, Latin America, the Middle East, Africa, Asia and the Pacific region. A respective agreement between Bayer Schering Pharma and ProStrakan Group plc. was signed which grants Bayer exclusive marketing rights in these regions. Children in the world's poorest countries to get free insulin
Novo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo. Roche signs definitive agreement to acquire Memory Pharmaceuticals
Roche and Memory Pharmaceuticals have announced that the two companies have signed a definitive merger agreement for Roche to fully acquire Memory in an all-cash transaction at a price of approximately USD 50 million. More Pharma News ...
Business & Industry
- Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
- CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders
- Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
- BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
- Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
Research & Development
- Candidate found to inhibit malignant melanoma growth
- A nasal spray protects against coronavirus infection - Effective also against recent immune-evasive variants
- 'Biohybrid' device could restore function in paralysed limbs
- Scientists use tardigrade proteins for human health breakthrough
- DNA treatment could delay paralysis that strikes nearly all patients with ALS
- Scientists reveal a potential new approach to treating liver cancer
- Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA grants Accelerated Approval for Alzheimer's disease treatment
- FDA approves new HIV drug for adults with limited treatment options
- FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
- FDA approves first gene therapy to treat adults with Hemophilia B
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease